Valuation
- Market cap
- 42,754,800,000
- Revenue TTM
- $11,157,000,000
- Net income TTM
- $914,000,000
- PE ratio
- 0.00
- Forward PE
- 23.24
- Profit margin
- 8.19%
- Debt to equity
- 0.50
Trading
- Volume
- 23,200
- Avg volume
- 23,658
- Day's range
- $96.59 – $98.44
- Shares out
- 440,000,000
- Stochastic %K
- 90%
- Beta
- 0.58
- Analysts
- Strong Sell
- Price target
- $96.80
Company profile
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical i...
Show more
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 41 61 324 11 11
- Website
- https://www.sandoz.com
- Address
- Centralbahnstrasse 4, Basel, Switzerland
Latest news
No headlines yet.
